CTL019在复发/难治性B细胞急性淋巴细胞白血病和慢性淋巴细胞白血病中的细胞动力学
对103例接受CTL019治疗的复发/难治性B细胞急性淋巴细胞白血病(ALL)和慢性淋巴细胞白血病(CLL)患者进行正式细胞动力学分析,采用定量聚合酶链反应和流式细胞术检测外周血和骨髓中CTL019。外周血CTL019水平通常在输注后10至14天达峰,随后缓慢下降;获完全缓解(CR)/血细胞计数未完全恢复的CR患者外周血CTL019水平更高,最大浓度和曲线下面积均高于无应答患者(每项P<.0001)。CTL019转基因水平在外周血中可检测至780天,在骨髓和脑脊液中观察到运输和持续存在;在儿童ALL中,CTL019扩增与细胞因子释放综合征(CRS)严重程度及输注前肿瘤负荷相关。
要点
- 外周血CTL019水平通常在输注后10至14天达峰,随后缓慢下降。
- CR/CRi患者外周血CTL019的最大浓度和曲线下面积均高于无应答患者(每项P<.0001)。
- 儿童ALL中CTL019扩增与CRS严重程度及输注前肿瘤负荷相关。
核心结论
- 本文首次对两种疾病进行详细正式的细胞动力学呈现,强调应用体内细胞动力学分析来表征CTL019治疗的临床疗效和CRS严重程度的重要性。
研究设计与样本
- 对103例在两种不同疾病(ALL和CLL)中接受CTL019治疗的患者进行正式细胞动力学分析。
- 采用定量聚合酶链反应和流式细胞术检测外周血和骨髓中的CTL019。
主要发现
- 外周血CTL019水平通常在输注后10至14天达峰,随后随时间缓慢下降。
- CR/CRi患者外周血CTL019水平更高,最大浓度和曲线下面积值均高于无应答患者(每项P<.0001)。
- 外周血中CTL019转基因水平可检测至780天。
- 在骨髓和脑脊液中观察到CTL019的运输和持续存在。
- 在儿童ALL中,CTL019扩增与CRS严重程度及输注前肿瘤负荷相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing cells. We previously reported that CTL019 achieved impressive clinical efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), including the expansion and persistence of CTL019 cells, which correlates with response to therapy. Here, we performed formal cellular kinetic analyses of CTL019 in a larger cohort of 103 patients treated with CTL019 in 2 different diseases (ALL and CLL). CTL019 was measured in peripheral blood and bone marrow, using quantitative polymerase chain reaction and flow cytometry. CTL019 levels in peripheral blood typically peaked at 10 to 14 days postinfusion and then declined slowly over time. Patients with complete response (CR)/CR with incomplete count recovery had higher levels of CTL019 in peripheral blood, with greater maximal concentration and area under the curve values compared with nonresponding patients (P < .0001 for each). CTL019 transgene levels were measurable up to 780 days in peripheral blood. CTL019 trafficking and persistence were observed in bone marrow and cerebrospinal fluid. CTL019 expansion correlated with severity of cytokine release syndrome (CRS) and preinfusion tumor burden in pediatric ALL. The results described here are the first detailed formal presentation of cellular kinetics across 2 diseases and highlight the importance of the application of in vivo cellular kinetic analyses to characterize clinical efficacy and CRS severity associated with CTL019 therapy.
引用
- Mueller KT, Maude SL, Porter DL, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017. PMID: 28935694. doi:10.1182/blood-2017-06-786129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。